Corbus Pharmaceuticals
Update in progressCRBP (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company developing therapies for cancer and obesity. Its pipeline includes CRB-701, an antibody-drug conjugate that targets Nectin-4 on tumor cells to deliver the cytotoxic payload monomethyl auristatin E, and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity. Founded in 2009, it is based in Norwood, Massachusetts.
Company score
- Sentiment
- 0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Yuval Cohen Ph.D.
- Founded2009
- Employees36
- Websitewww.corbuspharma.com
Identifiers
- ISINUS21833P3010
- FIGIBBG0078PJKQ7
- CUSIP21833P103
- CIK0001595097